Evidence map›Paper›PMID 32116719›Full record

ArticleFrontiers in pharmacology2020

Protective Effects of Amlodipine Pretreatment on Contrast-Induced Acute Kidney Injury And Overall Survival In Hypertensive Patients.

Wen-Jun Yin, Ling-Yun Zhou, Dai-Yang Li, Yue-Liang Xie, Jiang-Lin Wang, Shan-Ru Zuo, Kun Liu, Can Hu, Ge Zhou, Lin-Hua Chen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Wen-Jun YinDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Ling-Yun ZhouDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Dai-Yang LiDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Yue-Liang XieDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Jiang-Lin WangDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Shan-Ru ZuoDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Kun LiuDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Can HuDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Ge ZhouDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Lin-Hua ChenDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Hui-Qing YangDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Xiao-Cong ZuoDepartment of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, China.
Third Xiangya Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroudContrast-induced acute kidney injury (CI-AKI) is the most common adverse reaction caused by contrast media, which has been reported to prolong hospitalization and increase mortality and morbidity. The hypertensive population has proved susceptible to CI-AKI. Unfortunately, no therapeutic has been shown to prevent and cure CI-AKI effectively. A few studies have shown the protection of amlodipine on renal function, but the relationship between amlodipine and CI-AKI in hypertensive group is unknown, we aimed to study the effects of amlodipine on CI-AKI and overall survival in a large Chinese hypertensive cohort.

methodsA retrospective, matched, cohort study was conducted among adults hospitalized at the Third Xiangya Hospital of Central South University from October 2007 to May 2017. CI-AKI was the primary end point of the trial, time-related all-cause mortality (including in-hospital) and length of hospital stay were the secondary end points. Propensity Score Matching was used to reduce the effect of selection bias and potential confounding.

results868 patients with and 1,798 ones without amlodipine before contrast administration were included. The incidence of CI-AKI was 10.50%. The unadjusted, adjusted, and propensity-score matched incidence of CI-AKI were lower in patients treated with amlodipine (OR, 0.650;

conclusionIn conclusion, we first found amlodipine treatment before contrast exposure played a role in protecting hypertensive patients from CI-AKI and prolonging survival.

Indexed as

acute kidney injuryamlodipinecontrast-induced acute kidney injurycontrast mediahypertensionrisk factor

Identifiers

PMID32116719
PMCPMC7027359
OpenAlexW3005891656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.